Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Decreased by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC lowered its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 71.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 7,123 shares of the company’s stock after selling 17,877 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Protagonist Therapeutics were worth $275,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in shares of Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock valued at $78,034,000 after acquiring an additional 1,733,662 shares during the period. State Street Corp increased its position in shares of Protagonist Therapeutics by 52.9% during the 3rd quarter. State Street Corp now owns 3,183,542 shares of the company’s stock valued at $143,259,000 after purchasing an additional 1,101,218 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after buying an additional 310,804 shares during the period. RTW Investments LP raised its position in Protagonist Therapeutics by 2.6% in the third quarter. RTW Investments LP now owns 5,426,112 shares of the company’s stock worth $244,175,000 after acquiring an additional 139,708 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in Protagonist Therapeutics during the third quarter valued at approximately $5,665,000. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 0.0 %

Shares of PTGX opened at $38.67 on Monday. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $48.89. The company’s fifty day moving average is $38.61 and its 200-day moving average is $41.86. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of 14.54 and a beta of 2.22.

Insiders Place Their Bets

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 26,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total value of $1,162,200.00. Following the transaction, the insider now directly owns 46,444 shares of the company’s stock, valued at $2,076,046.80. The trade was a 35.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the transaction, the chief executive officer now owns 435,208 shares of the company’s stock, valued at approximately $20,437,367.68. The trade was a 15.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 207,957 shares of company stock valued at $9,611,739 over the last three months. 5.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

PTGX has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. StockNews.com downgraded shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group initiated coverage on shares of Protagonist Therapeutics in a report on Friday, December 6th. They set a “neutral” rating and a $47.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.